Interferon-alpha2b

04/01/2002 - "Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C."
01/01/2001 - "Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study."
02/01/1998 - "In this study, 103 patients with chronic hepatitis C were treated with 3 MIU IFN-alpha2b three times weekly for 24 weeks, followed by 24 weeks of observation. "
07/01/2006 - "To examine how these immunologic responses vary with currently available regimens for chronic hepatitis C, cell populations purified from human peripheral blood mononuclear cells (PBMC) were treated with the clinically available combinations of pegylated IFN-alpha2b (PEG-IFN-alpha2b) + RBV, IFN-alphacon1 + RBV, or IFN- alphacon1 + IFN-gamma1b, and activation of cellular immune system components was monitored. "
11/01/2004 - "Effect of single-dose administration of recombinant interferon-alpha2b on gastric myoelectrical activity in patients with chronic hepatitis C."

03/01/2003 - "In contrast, dose interferon-alpha2b has been shown to improve relapse-free survival and likely improves melanoma-specific survival as well. "
03/14/2020 - "Based on this clinical finding, the current study sought to investigate the influence of IFN-alpha1b on the antitumor immunity of melanoma, with interferon-alpha2b (IFN-alpha2b) used as a control. "
01/01/2020 - "Subgroup analyses of two large EORTC adjuvant interferon-alpha2b (IFNα-2b) vs observation randomised trials demonstrated that a treatment benefit was observed only in patients with an ulcerated melanoma without palpable nodes (hazard ratio [HR] for recurrence-free survival [RFS] was 0.69). "
03/01/2003 - "Despite the use of a variety of cytotoxic and immunotherapeutic agents in adjuvant trials in patients following resection of high-risk early cutaneous melanoma, only interferon-alpha2b (IFN-alpha) has shown reproducible efficacy. "
03/14/2020 - "<strong>CONCLUSIONS</strong> IFN-alpha1b has an immunostimulatory activity similar to IFN-alpha2b and possesses milder adverse effects on immune checkpoints and stronger inhibitory effects on melanoma cell growth than IFN-alpha2b. "

08/01/2008 - "Neutralization of IFN-gamma downregulates the IFN-alpha2b mediated CXCL10 release, suggesting the active role of IFN-gamma in the transduction of chemotactic signal for the migration of cytotoxic T/NK cells at the tumor site."
10/01/2006 - "After HAK-1B cells were transplanted into nude mice, various doses of PEG-IFN-alpha2b or IFN-alpha2b were administered, and tumor volume, weight, histology, and IFNAR-2 expression were examined. "
10/01/2006 - "In conclusion, IFN-alpha2b couldenhance the proapoptotic effects of TGFbeta1, in early stages of hepatocarcinogenesis, which could be highly beneficial in cancer therapy."
02/01/2007 - "A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors."
03/01/1997 - "In studies in which two recombinant IFN-alpha preparations were directly compared in cancer patients, those given IFN-alpha2a were found to have neutralizing antibodies in their serum significantly more often than those given IFN-alpha2b (p <0.001). "

01/05/2011 - "Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation."
09/01/2007 - "This is the first report of a complete IFNGR1 deficiency treated with adjuvant IFN-alpha2b for disseminated MAC infection."
03/01/2002 - "ALT levels flared up in 3 treated and 9 untreated patients (p = 0.07), suggesting that these flare-ups are related to the natural course of chronic HCV infection rather than to IFN-alpha2b. "
01/20/1999 - "A similar response against HIV-LAI infection was obtained after pretreatment with 100 U/ml of recombinant IFN-alpha2b or IFN-beta. "
12/01/1996 - "These findings suggest that high-dose interferon-alpha2b is well tolerated and effective in preventing a chronic course of hepatitis C infection."

05/01/2004 - "This study examines SI in hepatitis C patients untreated and treated with interferon-alpha2b, a medication commonly associated with depression. "
12/01/1996 - "The Australian Hepatitis C Study Group conducted a trial of 230 patients that compared the standard 3 MU three times a week six-month course of IFN-alpha2b with 5 MU three times a week for six months (5 MU group) or 3 MU three times a week for two years (two-year group). "
12/01/1996 - "High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study."
08/01/2006 - "Twenty-three patients with recurrent hepatitis C received combination therapy of IFN-alpha2b plus RBV. "
12/01/1996 - "These findings suggest that high-dose interferon-alpha2b is well tolerated and effective in preventing a chronic course of hepatitis C infection."